Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (UM1 Clinical Trial Required)

    NIMH plans funding for a research network to study the real-world effectiveness, safety, and implementation of rapid-acting psychotropic drugs for serious mental illnesses.

    OverviewSimilar Grants
    OverviewSimilar Grants

    This grant was recently updated

    This grant has transitioned from forecasted to posted and is now accepting applications.

    Funder: National Institutes of Health

    Due Dates: June 10, 2027 (Application)

    Funding Amounts: $12 million estimated total program funding; 3 expected awards; project periods up to 5 years

    Summary: Supports coordinated clinical trial networks generating real-world evidence on safe, effective, and sustainable delivery of rapid-acting psychotropic interventional drugs.

    Key Information: Only large-scale pragmatic clinical trial networks are supported; foreign organizations and foreign components are not allowed.


    Description

    The National Institute of Mental Health (NIMH) and National Institute on Drug Abuse (NIDA) support the establishment of a Rapid-Acting Psychotropic Interventional Drugs–Clinical Trials Network (RAPIDs-CTN). The program seeks actionable evidence for routine clinical use of treatments that reduce symptoms within hours to days, focusing on serious mental illnesses, treatment-resistant psychiatric conditions, and urgent suicide risk.

    Networks must combine a centralized Data Coordinating Center (DCC) with federated clinical sites conducting pragmatic trials in real-world care settings. Priorities include clinical effectiveness and safety, workforce and monitoring needs, retreatment frequency, healthcare costs, and sustainable delivery models. The milestone-driven UM1 cooperative agreement supports network establishment and pilot studies in Years 1–2, followed by full-scale pragmatic trials in Years 3–5. Networks should be able to adapt to newly approved treatments.


    Atom

    See the full grant listing

    Sign in to view full eligibility details, sources, similar grants, and AI-powered analysis.